Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The effect was strongest among women with 25(OH)D level ≥30ng/ml at study entry: aOR = 0.54 (0.33 to 0.88), p = 0.01, whereas no significant effect was observed among women with 25(OH)D level <30ng/ml at study entry: aOR = 0.84 (0.62 to 1.15), p = 0.25.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted random effects combined analyses of the treatment effect, individual patient data (IPD) meta-analyses, and analyses stratified by 25(OH)D level at study entry.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials

Review / evidence synthesis · PLoS ONE · 2017

Original publication title

Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials

Helene M. Wolsk; Bo L. Chawes; Augusto A. Litonjua; Bruce W. Hollis; Johannes Waage; Jakob Stokholm; Klaus Bønnelykke; Hans Bisgaard; Scott T. Weiss

© 2017 Wolsk et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This combined analysis shows that vitamin D supplementation during pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, especially among women with 25(OH)D level ≥ 30 ng/ml at randomization, where the risk was almost halved. Future studies should examine the possibility of raising 25(OH)D levels to at least 30 ng/ml early in pregnancy or using higher doses than used in our studies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To perform a combined analysis of the two trials and investigate whether maternal 25-hydroxy-vitamin D (25(OH)D) level at trial entry modified the intervention effect.

Source: Objective

Abstract: What methods does the paper describe?

VDAART (N = 806) and COPSAC2010. (N = 581) randomized pregnant women to daily high-dose vitamin D3 (4,000 IU/d and 2,400 IU/d, respectively) or placebo. All women also received a prenatal vitamin containing 400 IU/d vitamin D3. The primary outcome was asthma/recurrent wheeze from 0-3yrs. Secondary end-points were specific IgE, total IgE, eczema and lower respiratory tract infections (LRTI). We conducted random effects combined analyses of the treatment effect, individual patient data (IPD) meta-analyses, and analyses stratified by 25(OH)D level at study entry.

Source: Methods

Abstract: Results

The analysis showed a 25% reduced risk of asthma/recurrent wheeze at 0-3yrs: adjusted odds ratio (aOR) = 0.74 (95% CI, 0.57 to 0.96), p = 0.02. The effect was strongest among women with 25(OH)D level ≥30ng/ml at study entry: aOR = 0.54 (0.33 to 0.88), p = 0.01, whereas no significant effect was observed among women with 25(OH)D level <30ng/ml at study entry: aOR = 0.84 (0.62 to 1.15), p = 0.25. The IPD meta-analyses showed similar results. There was no effect on the secondary end-points.

Source: Results

Abstract: Conclusions

This combined analysis shows that vitamin D supplementation during pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, especially among women with 25(OH)D level ≥ 30 ng/ml at randomization, where the risk was almost halved. Future studies should examine the possibility of raising 25(OH)D levels to at least 30 ng/ml early in pregnancy or using higher doses than used in our studies.

Source: Conclusions
Authors’ abstract

Background

We recently published two independent randomized controlled trials of vitamin D supplementation during pregnancy, both indicating a >20% reduced risk of asthma/recurrent wheeze in the offspring by 3 years of age. However, neither reached statistical significance.

Objective

To perform a combined analysis of the two trials and investigate whether maternal 25-hydroxy-vitamin D (25(OH)D) level at trial entry modified the intervention effect.

Methods

VDAART (N = 806) and COPSAC2010. (N = 581) randomized pregnant women to daily high-dose vitamin D3 (4,000 IU/d and 2,400 IU/d, respectively) or placebo. All women also received a prenatal vitamin containing 400 IU/d vitamin D3. The primary outcome was asthma/recurrent wheeze from 0-3yrs. Secondary end-points were specific IgE, total IgE, eczema and lower respiratory tract infections (LRTI). We conducted random effects combined analyses of the treatment effect, individual patient data (IPD) meta-analyses, and analyses stratified by 25(OH)D level at study entry.

Results

The analysis showed a 25% reduced risk of asthma/recurrent wheeze at 0-3yrs: adjusted odds ratio (aOR) = 0.74 (95% CI, 0.57 to 0.96), p = 0.02. The effect was strongest among women with 25(OH)D level ≥30ng/ml at study entry: aOR = 0.54 (0.33 to 0.88), p = 0.01, whereas no significant effect was observed among women with 25(OH)D level <30ng/ml at study entry: aOR = 0.84 (0.62 to 1.15), p = 0.25. The IPD meta-analyses showed similar results. There was no effect on the secondary end-points.

Conclusions

This combined analysis shows that vitamin D supplementation during pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, especially among women with 25(OH)D level ≥ 30 ng/ml at randomization, where the risk was almost halved. Future studies should examine the possibility of raising 25(OH)D levels to at least 30 ng/ml early in pregnancy or using higher doses than used in our studies.

Trial registration

COPSAC2010: ClinicalTrials.gov NCT00856947; VDAART: ClinicalTrials.gov NCT00920621

Publication and source details

Original title: Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials

Helene M. Wolsk; Bo L. Chawes; Augusto A. Litonjua; Bruce W. Hollis; Johannes Waage; Jakob Stokholm; Klaus Bønnelykke; Hans Bisgaard; Scott T. Weiss

PLoS ONE · 2017

Competing Interests: HB has been consultant for Chiesi and Boehringer Ingelheim. AAL reports grants from NIH, during the conduct of the study and author royalties from UpToDate, Inc. and Humana Springer Press. STW reports grants from the NIH, and speakers fees from Illumina Corp during the conduct of the study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

‡ These authors are co-first authors on this work.

* E-mail: scott.weiss@channing.harvard.edu
© 2017 Wolsk et al2017Wolsk et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteU01HL091528http://orcid.org/0000-0001-7196-303XWeiss Scott T. National centers for Advancing Translational SciencesU54TR001012The Lundbeck FoundationR16-A1694Bisgaard Hans The Danish Ministry of Health903516Bisgaard Hans http://dx.doi.org/10.13039/100007398Strategiske Forskningsråd0603-00280BBisgaard Hans http://dx.doi.org/10.13039/501100003554LundbeckfondenR191-2015.1571Wolsk Helene M. http://dx.doi.org/10.13039/100008593European Respiratory SocietyFellowship, LTRF, 2016Chawes Bo L. http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood Institute5 R01 HL091528http://orcid.org/0000-0001-7196-303XWeiss Scott T. VDAART was supported by U01HL091528 and 5 R01 HL091528 from the National Heart, Lung, and Blood Institute. Additional support was provided by U54TR001012 from the National Centers for Advancing Translational Sciences (NCATS) for participant visits at Boston Medical Center. COPSAC is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation Grant (no. R16-A1694); The Danish Ministry of Health (Grant no. 903516); Danish Council for Strategic Research (Grant no. 0603-00280B) and The Capital Region Research Foundation (no grant no.) have provided core support for COPSAC. HMW was supported by an unrestricted grant from the Lundbeck Foundation (R191-2015.1571). BC was supported by a European Respiratory Society fellowship, LTRF, 2016. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:15:28.153690+00:00

DOI: 10.1371/journal.pone.0186657 · PMC5659607